Oncotarget came to the limelight in 2010, and this was facilitated by the significant impact that was encountered in the medical field as a result of data sharing. Oncology is a topic that is extremely wide, and in the same manner, oncologists tend to face the humongous task of covering all the issues under Oncology to efficiently help their patients and come up with suitable solutions to cancer. Oncotarget encompasses all fields of specialization under Oncology, and it is assisting specialists who have been involved in the treatment of chronic diseases for decades. The primary technique that is used on Oncotarget is peer reviewing. The method has proved to be very useful in bringing specialist’s together so that they can be able to compare different scientific findings. Peer reviews are a must for any oncologist who wants his/her work to be published on Oncotarget. Based on the number of peer reviews that a journal can gain, the editors can enhance the information delivery to readers. Peer reviewing makes it possible to ensure that accurate data from a research process can be offered.
Oncotarget editors encourage specialists to provide peer reviews to particular journals that are addressing issues of oncology. When a journal is reviewed by many experts, then Oncotarget editors can give it a higher priority as it indicates that the data presented is highly credible. Invitations are sent to medical professionals to encourage them to review medical journals that have been written by other scientists. It’s not a must for a doctor to engage in peer reviewing as one may feel that they are not qualified to participate in the process. In such a case, oncologists to who have received invitations are required to notify the editors early enough so that other professionals can be engaged. Mikhail Blagosklonny is one of the primary editors of Oncotarget, and he also helped in the establishment of the web portal. Mikhail Blagosklonny believes that suitable treatment can be found when information is shared in the proper manner. Working with other professionals makes it possible to avoid mistakes that are typically made when a person works alone.
Mikhail Blagosklonny’s engagement in medical matters has been going on for a long time, and this has exposed him to some of the suitable techniques that can be used to overcome challenges that have existed since time in memorial. He considers sharing of information to be a methodology that will make it possible to move forward and tackle future challenges.IntegraGen is another company that has been offering its services in the field of Oncology, and it recently published a research on tumor samples that is currently available on Oncotarget. The study has made it possible to uncover facts about tumors that develop in different parts of the body, and as a result, various methods of diagnosis can be combined to understand the causative agents of cancer. Such results are greatly revolutionizing the field of science, and they continually put doctors at the forefront in the fight against ailments.
As an American business professional, Eric Lefkofsky knows that it is important to keep up with an entrepreneurial spirit no matter what business he is in. Eric Lefkofsky worked with many businesses, but Tempus has been one of the most influential ones that he has been a part of.
Eric Lefkofsky made the decision to launch Tempus. This is a company that has worked hard to help cure cancer and is something everyone can get behind whether they have been very successful, like EricLefkofsky or not. This is a startup company that was started after he had already seen a lot of success and was something that he truly felt he needed to be a part of. It was one of the many ways that he was able to help people with the success that he has had while he has been in the sales business.
Tempus created to help people. It is made to help people who have cancer and who are trying to work toward a cure for it. The app is one that was designed for people to be able to use easily and it contributes toward a greater good in the way that things work for the business. It is something that has made a lot of good improvements for people who have cancer and for people who want to find a cure to cancer, which is actually most people in the world since nearly everyone has been touched by it in some way.
While Tempus has been a great startup idea for Eric Lefkofsky, it is something that he wants to take even further. He wants to move forward with the company and with other companies to provide people with even more solutions for cancer and for other health problems. Unlike the other endeavors that Eric Lefkofsky has had, this is one of the first ones that is health related and is something that is going to make things much better for the companies and for the people who make the decision to use it to help cure cancer and the associated problems.
Despite the fact that Eric Lefkofsky has been extremely successful, he has worked hard to make sure that things are better and that things are being done the right way in different communities. He wants to make sure that people who did not have a chance before are now being taken care of and that they are getting what they need out of the different things that he has offered. He has been philanthropic in most of the things that he does and this has contributed to continued success that he has in the sales fields that he is prominent in.
While he is really philanthropic and even successful, he has seen the need for humility. He wants to make sure that things are done the right way and that people are comfortable with them. Eric Lefkofsky knows that remaining humble is one of the best ways to continue success. He is always humble no matter how much success he has. He wants to make sure that things are better for himself, as well as other people, so that he can make sure that things are right for the communities that play a major role in all of his business efforts.
About Eric Lefkofsky: norcal.news/news/23733-eric-lefkofsky-searches-coast-coast-cure
Oncotarget is a medical journal that publishes the latest and greatest in medical science. The journal was started and is edited by Mikhail Blagosklonny. The goal of the journal is to provide relevant studies about oncology, which has to do with treatment and prevention of cancer. Follow Oncotarget on Twitter.
Oncotarget aims to provide awareness of certain treatments that are emerging from the latest studies in oncology. The studies will detail responses of the patient and their cancer during certain stages of treatment. The cancer community can freely access the journal and potentially use the data for further research, awareness or as a basis for new medical trials.
Oncotarget is accepted by many large medical indexes as a reliable source for published journals. Index Medicus, PubMed, BIOSIS and Scopus all include references to studies published by them. International universities, like the University of Gothenburg, also use references from the journal.
Oncology is a competitive field of medicine tackling one of the most stubborn diseases known to man, cancer. The roots of this field of medicine have roots going all the way back to Ancient Greece. The name of this field of medicine was even derived from the Greek word that means tumor. Visit his profile on Google Scholar.
The first priority of any oncologist is to prevent risk factors associated with cancer. This means that patients should stop smoking, drinking, using drugs, or eating diets that are known to exaggerate the growth of cancer. There are different types of oncologists that come together to create cancer management plans. A radiation oncologist, pathologists, organ-specific experts and surgical oncologists are parts of a typical oncology team.
For a long time, cancer treatment options were riddled with chemo-therapies, which did not differentiate between good and bad cells and therefore ended up killing them. Clay Siegall saw this and embarked on a journey to develop targeted therapies to treat major unmet needs. In the late 1990s, Mr. Siegall co-founded Seattle Genetics on the pillars of scientific innovation, rigorous research and drug development practices. The firm is developing a diverse portfolio of clinical and pre-clinical product candidates targeting a variety of cancer and autoimmune indications.
Clay Siegall, a scientist by training, has decades of experience in cancer research. He has a PhD. in Genetics from George Washington University and a Bachelor of Science in Zoology from the University of Maryland from which he received the Alumnus of the year for Math, Computer, and Natural Science in 2013. He also received the Pacific Northwestern Ernst & Young Entrepreneur of the year in the healthcare category in 2012.
Clay Siegall’s Impressive Experience in Cancer Research
Mr. Siegall holds 15 patents in a bid to advance research into cancer treatments and has been published more than 70 times. He has a passion for sharing his tremendous experiences and knowledge in new research methods and discoveries. Before the birth of Seattle Genetics, Clay worked at Squibb Pharmaceutical Research Institute, National Cancer Institute and the National Institute of Health. Dr. Clay Siegall serves on the Board of Governors of Fred Hutchinson Cancer Research Business and Board of Directors of Mirna Therapeutics. Mirna is hoping to benefit from his extensive knowledge.
Dr. Siegall has shown excellent efforts in ensuring the success of Seattle Genetics for the good of cancer patients everywhere. Over five years the stock price of the company has tripled. He has raised more than $675 Million through public donation and private funding deals. Under Dr. Clay Siegall’s stewardship, the company has secured a position of pride in the field of Antibody Drug Conjugates (ADCs). In 2011, the FDA approved ADCETRIS which is now available to help cancer patients in more than 65 countries. A perfect world for Dr. Clay Siegall is one in that cancer patients no longer have to suffer.